Rhythm Pharmaceuticals Q3 net product revenue rises to $92.1 million; net loss narrows
Rhythm Pharmaceuticals reported third-quarter 2026 net product revenue of $92.1 million from global IMCIVREE sales, up from $51.3 million a year earlier, and a net loss attributable to common stockholders of $42.4 million, or $0.61 per share, compared with $54.3 million, or $0.82 per share, a year earlier. The company also secured a five-year term loan facility providing access to up to $750 million and amended its bivamelagon license with LG Chem, which requires $350 million in fixed payments over four years, so shareholders face both stronger sales and a larger financing and licensing commitment.
Key points
- Q3 2026 net product revenue was $92.1 million, up 29% from the second quarter of 2026 and up from $51.3 million in Q3 2025.
- Q3 2026 net loss attributable to common stockholders was $42.4 million, or $0.61 per share, versus $54.3 million, or $0.82 per share, in Q3 2025.
- Cash, cash equivalents and short-term investments were $320.9 million as of September 30, 2026, excluding the $250 million initial draw on the term loan and a $70 million payment due to LG Chem.
- Non-GAAP operating expenses for 2026 are expected to be $360 million to $380 million.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.